论文部分内容阅读
树突状细胞 (DC)是最有效的抗原递呈细胞 (APC) ,在诱发抗肿瘤免疫中担任重要角色 ,并作为肿瘤疫苗在临床医学中得到不断发展。早期临床试验表明 ,基于树突状细胞的疫苗在泌尿生殖系统肿瘤患者的应用中体现了低毒性 ,且证实了在某些患者出现了免疫和临床反应。尽管其发展仍处于初级阶段 ,但最终产生临床有效的肿瘤疫苗的前景变得更加现实。
Dendritic cells (DCs) are the most potent antigen presenting cells (APC) and play an important role in inducing anti-tumor immunity and have been evolving in clinical medicine as tumor vaccines. Early clinical trials have shown that dendritic cell-based vaccines exhibit low toxicity in the application of genitourinary tumor patients and confirm the emergence of immunological and clinical responses in some patients. Although its development is still in its infancy, the prospect of eventually producing a clinically effective tumor vaccine has become more realistic.